High coverage needle/syringe programs for people who inject drugs in low and middle income countries: a systematic review

BMC Public Health - 2013
Don C Des Jarlais1, Jonathan P Feelemyer1, Shilpa N Modi1, Abu Abdul-Quader2, Holly Hagan3
1The Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, New York City, USA
2Centers for Disease Control and Prevention, Atlanta, USA
3College of Nursing, New York University, New York City, USA

Tóm tắt

Persons who inject drugs (PWID) are at an elevated risk for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection. In many high-income countries, needle and syringe exchange programs (NSP) have been associated with reductions in blood-borne infections. However, we do not have a good understanding of the effectiveness of NSP in low/middle-income and transitional-economy countries. A systematic literature review based on PRISMA guidelines was utilized to collect primary study data on coverage of NSP programs and changes in HIV and HCV infection over time among PWID in low-and middle-income and transitional countries (LMICs). Included studies reported laboratory measures of either HIV or HCV and at least 50% coverage of the local injecting population (through direct use or through secondary exchange). We also included national reports on newly reported HIV cases for countries that had national level data for PWID in conjunction with NSP scale-up and implementation. Studies of 11 NSPs with high-coverage from Bangladesh, Brazil, China, Estonia, Iran, Lithuania, Taiwan, Thailand and Vietnam were included in the review. In five studies HIV prevalence decreased (range −3% to −15%) and in three studies HCV prevalence decreased (range −4.2% to −10.2%). In two studies HIV prevalence increased (range +5.6% to +14.8%). HCV incidence remained stable in one study. Of the four national reports of newly reported HIV cases, three reported decreases during NSP expansion, ranging from −30% to −93.3%, while one national report documented an increase in cases (+37.6%). Estimated incidence among new injectors decreased in three studies, with reductions ranging from −11/100 person years at risk to −16/100 person years at risk. While not fully consistent, the data generally support the effectiveness of NSP in reducing HIV and HCV infection in low/middle-income and transitional-economy countries. If high coverage is achieved, NSP appear to be as effective in LMICs as in high-income countries. Additional monitoring and evaluation research is needed for NSPs where reductions in HIV/HCV infection among PWID are not occurring in order to identify and correct contributing problems.

Từ khóa


Tài liệu tham khảo

Alter MJ: Epidemiology of viral hepatitis and HIV co-infection. Journal of Hepatology. 2006, 44, Supplement 1 (0): S6-S9.

Alter MJ: Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007, 13 (17): 2436-2441.

Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, Wodak A, Panda S, Tyndall M, Toufik A, et al: Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008, 372 (9651): 1733-1745. 10.1016/S0140-6736(08)61311-2.

WHO: Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users. 2004, Geneva: WHO, 61-

World Health Organization: WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. 2009, Geneva: WHO

Strathdee SAVD: The effectiveness of needle exchange programs: A review of the science and policy. AIDS Reader. 2001, 1 (16): 1-31.

Hurley SF, Jolley DJ, Kaldor JM: Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet. 1997, 349 (9068): 1797-1800. 10.1016/S0140-6736(96)11380-5.

Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D: Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction. 2010, 105 (5): 844-859. 10.1111/j.1360-0443.2009.02888.x.

Salter ML, Go VF, Minh NL, Gregowski A, Ha TV, Rudolph A, Latkin C, Celentano DD, Quan VM: Influence of Perceived Secondary Stigma and Family on the Response to HIV Infection Among Injection Drug Users in Vietnam. AIDS Educ Prev. 2010, 22 (6): 558-570. 10.1521/aeap.2010.22.6.558.

Booth RE, Kennedy J, Brewster T, Semerik O: Drug injectors and dealers in Odessa, Ukraine. J Psychoactive Drugs. 2003, 35 (4): 419-426. 10.1080/02791072.2003.10400488.

Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, May M, Taylor A, De Angelis D, Cameron S, et al: The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011, 106 (11): 1978-1988. 10.1111/j.1360-0443.2011.03515.x.

Des Jarlais DC, Arasteh K, McKnight C, Hagan H, Perlman DC, Torian LV, Beatice S, Semaan S, Friedman SR: HIV infection during limited versus combined HIV prevention programs for IDUs in New York City: the importance of transmission behaviors. Drug Alcohol Depend. 2010, 109 (1–3): 154-160.

UNAIDS: Combination HIV Prevention: Tailoring and Coordinating Biomedical, Bheavioural and Structural Strategies to Reduce New HIV Infections. 2010, Geneva: UNAIDS, 31-

Vlahov D, Robertson AM, Strathdee SA: Prevention of HIV infection among injection drug users in resource-limited settings. Clin Infect Dis. 2010, 50 (Suppl 3): S114-S121.

Burrows D: High Coverage Sites: HIV Prevention among Injecting Drug Users in Transitional and Developing Countries. UNAIDS Best Practice Collection. 2010, Geneva: UNAIDS

Vickerman P, Hickman M, Rhodes T, Watts C: Model projections on the required coverage of syringe distribution to prevent HIV epidemics among injecting drug users. J Acquir Immune Defic Syndr. 2006, 42 (3): 355-361. 10.1097/01.qai.0000219788.73539.47.

Latkin CA, Vlahov D, Anthony JC: Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction. 1993, 88 (4): 517-526. 10.1111/j.1360-0443.1993.tb02058.x.

World Bank: Country and Lending Groups by Income-World Bank Country and Lending Groups. 18 July 2011, Washington DC: World Bank

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009, 62 (10): e1-e34. 10.1016/j.jclinepi.2009.06.006.

Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009, 62 (10): 1006-1012. 10.1016/j.jclinepi.2009.06.005.

IHRA: The Global State of Harm Reduction 2010: Key Issues for Broadening the Response. 2010, London, United Kingdom: International Harm Reduction Association, 59-63.

Egger M, Smith GD: Principles of and Procedures for Systematic Reviews. In Systematic Reviews in Health Care. 2008, United Kingdom: BMJ Publishing Group, 23-42.

Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, Myers B, Ambekar A, Strathdee SA: HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. The Lancet. 375 (9719): 1014-1028.

Wodak A, Cooney A: Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006, 41 (6–7): 777-813.

Gray J: Harm reduction in the hills of northern Thailand. Subst Use Misuse. 1998, 33 (5): 1075-1091. 10.3109/10826089809062208.

Caiaffa WT, Mingoti SA, Proietti FA, Carneiro-Proietti AB, Silva RC, Lopes AC, Doneda D: Estimation of the number of injecting drug users attending an outreach syringe-exchange program and infection with human immunodeficiency virus (HIV) and hepatitis C virus: the AjUDE-Brasil project. J Urban Health. 2003, 80 (1): 106-114. 10.1093/jurban/jtg106.

Wu Z, Luo W, Sullivan SG, Rou K, Lin P, Liu W, Ming Z: Evaluation of a needle social marketing strategy to control HIV among injecting drug users in China. AIDS. 2007, 21 (Suppl 8): S115-S122. 10.1097/01.aids.0000304706.79541.ef.

Azim T, Rahman M, Alam MS, Chowdhury IA, Khan R, Reza M, Chowdhury EI, Hanifuddin M, Rahman AS: Bangladesh moves from being a low-prevalence nation for HIV to one with a concentrated epidemic in injecting drug users. Int J STD AIDS. 2008, 19 (5): 327-331. 10.1258/ijsa.2007.007269.

Azim TI, Sharful Islam K, Quamrun N, Masud R, Nazmul A, Rumana S, Shah Alam M, Ezazul Islam C, Elizabeth O: 20 Years of HIV in Bangladesh: Experiences and Way Forward. The World Bank, UNAIDS. 2009, Washington D.C

Uuskula A, Des Jarlais DC, Kals M, Ruutel K, Abel-Ollo K, Talu A, Sobolev I: Expanded syringe exchange programs and reduced HIV infection among new injection drug users in Tallinn, Estonia. BMC Public Health. 2011, 11: 517-10.1186/1471-2458-11-517.

Hammett TM, Des Jarlais DC, Kling R, Kieu BT, McNicholl JM, Wasinrapee P, McDougal JS, Liu W, Chen Y, Meng D, et al: Controlling HIV Epidemics among Injection Drug Users: Eight Years of Cross-Border HIV Prevention Interventions in Vietnam and China. PLoS ONE. 2012, 7 (8): e43141-10.1371/journal.pone.0043141.

Center for Disease Management Ministry of Health: Current statistics on HIV/AIDS infection in the Islamic Republic of Iran. 2007, Tehran, Iran: Iranian Ministry of Health, 6-

Astrauskiene A: Needle and Sryinge Programmes Monitoring in Lithuania. 2010, Vilnius: Drug control department under the Government of the Republic of Lithuania

CDC Taiwan: National HIV/AIDS Surveillance Report. 2010, Tapei City

Hammett NDTTM: Annual New HIV Infection by mode of Transmission. Edited by: Jarlais DDD. 2010, New York City

Hammett TM, Kling R, Johnston P, Liu W, Ngu D, Friedmann P, Binh KT, Dong HV, Van LK, Donghua M, et al: Patterns of HIV prevalence and HIV risk behaviors among injection drug users prior to and 24 months following implementation of cross-border HIV prevention interventions in northern Vietnam and southern China. AIDS Educ Prev. 2006, 18 (2): 97-115. 10.1521/aeap.2006.18.2.97.

Des Jarlais DC, Kling R, Hammett TM, Ngu D, Liu W, Chen Y, Binh KT, Friedmann P: Reducing HIV infection among new injecting drug users in the China-Vietnam Cross Border Project. AIDS. 2007, 21 (Suppl 8): S109-S114. 10.1097/01.aids.0000304705.79541.34.

UNODC: Report: Regional Seminar on Reducing Harms of Drug Use in Middle East, West and Central Asia. 2008, Tehran: Office for the Islamic Republic of Iran

Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, Smith L, Wethers J, Milliken J, Mildvan D, et al: Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990–2001. AIDS. 2005, 19 (Suppl 3): S20-S25. 10.1097/01.aids.0000192066.86410.8c.

Paraskevis D, Nikolopoulos G, Tsiara C, Paraskeva D, Antoniadou A, Lazanas M, Gargalianos P, Psychogiou M, Malliori M, Kremastinou J, et al: HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report. Euro Surveillance. 2011, 16 (36):

Salminen M: Letter to the editor: HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report. Euro Surveill. 2011, 16 (41): author reply pii: 19987-

Kerr T, Small W, Buchner C, Zhang R, Li K, Montaner J, Wood E: Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. Am J Public Health. 2010, 100 (8): 1449-1453. 10.2105/AJPH.2009.178467.

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2458/13/53/prepub

Thông tin
Thông tin xuất bản

BMC Public Health

Thông tin tác giả